A new approach to cancer immunotherapy that uses one type of immune cell to kill another — rather than directly attacking the cancer — provokes a robust anti-tumor immune response that shrinks ovarian, lung, and pancreatic tumors in preclinical disease models, according to researchers. The study involved a twist on a type of therapy that uses immune cells known as CAR T cells.
Click here for original story, Targeting one type of immune cell with another slows cancer growth in preclinical studies
Source: ScienceDaily